H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Black Diamond Therapeutics (NASDAQ:BDTX) on Wednesday, setting a price target of $53, which is approximately 78.39% above the present share price of $29.71.
Burns expects Black Diamond Therapeutics to post earnings per share (EPS) of -$0.51 for the third quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Black Diamond Therapeutics, with an average price target of $51.5.
The analysts price targets range from a high of $53 to a low of $50.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$12.88 million. The company's market cap is $1.03 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 19.7% and a 59.57% success rate.
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.